Form D · Biotechnology
Histogen Inc.
San Diego, CA · CIK 0001383701
Offering snapshot reported Jul 26, 2022 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 26, 2022 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Nov 18, 2020 | Initial | $189,208 | No comparison | 7 | SEC filing |
| Jun 13, 2013 | Initial | $1,001,551 | No comparison | 21 | SEC filing |
| Feb 17, 2011 | Initial | $25,275,507 | No comparison | 16 | SEC filing |
| Oct 28, 2010 | Initial | $5,000,000 | No comparison | 15 | SEC filing |
| Nov 30, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $486K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-453646
Consists of: (i) (A) a pre-funded warrant to purchase 1,774,309 shares; (B) a Series A warrant to purchase 1,774,309 shares; and (C) a Series B warrant to purchase 1,774,309 shares; and (ii) placement agent warrants to purchase 124,202 shares.
Company has agreed to pay Wainwright (i) fee equal to 7.0% of the gross proceeds received by the Company, (ii) a management fee equal to 1.0% of the gross proceeds received by the Company; and (iii) $85,000 for non-accountable expenses.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Jul 26, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary C. Burgess | Executive |
| Charles J. Cashion | Executive |
| Jennifer Giottonini Cayer | Executive |
| Stephen Chang, Ph.D. | Director |
| David H. Crean | Director |
| David Crean, Ph.D. | Director |
| Moya Daniels | Executive |
| Rochelle Fuhrmann | Director |
| William Gerber | Director |
| William Gerber, M.D. | Director |
| David F. Hale | Director |
| Jonathan Jackson | Director |
| Daniel L. Kisner | Director |
| Daniel Kisner, M.D. | Director |
| Paul H. Klingenstein | Director |
| Susan A. Knudson | Executive |
| Louis Lacasse | Director |
| Martin Latterich | Executive |
| Shahzad Malik | Director |
| Shahzad Malik, M.D. | Director |
| Steven J. Mento | Director, Executive |
| Steven Mento, Ph.D. | Director |
| Gail K. Naughton | Executive |
| Richard W. Pascoe | Director, Executive |
| Marc Peret | Director |
| Marc Perret | Director |
| Joyce Reyes | Executive |
| Brian Satz | Director |
| Brian Satz, Esq. | Director |
| James Scopa | Director |
| Alfred P. Spada | Executive |
| Alfred P. Spada, Ph.D. | Executive |
| Harold Van Wart | Director |
| Harold Van Wart, M.D. | Director |
| Susan Windham Bannister | Director |
| Hayden Yizhuo Zhang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10655 Sorrento Valley Road Suite 200
San Diego, CA, 92121
San Diego, CA, 92121